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THE COST EFFECTIVENESS OF PLATELET RICH PLASMA VERSUS
CORTICOSTEROIDS IN THE TREATMENT OF LATERAL EPICONDYLITIS
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OBJECTIVES: To analyze the cost effectiveness of patelet rich plasma versus corti-
costeroids in the treatment of lateral epicondylitis in a Norwegian setting.
METHODS: A probabilistic Markov model was developed in Microsoft Excel, based
on clinical data from two papers reporting results from a randomized double blind
clinical trial comparing the effect of platelet rich plasma (L-PRP,n49) to cortico-
steroids (CCS, n51) as treatment of lateral epicondylitis (Peerbooms et al 2010,
Gosens et al 2011). The primary outcome of these papers, were Disability of Arm,
Shoulder and Hand (DASH) and the Numerical Pain Visual Analogue Scale (NPRS-
VAS). The study which was conducted in The Netherlands, showed statistically
significant differences on the visual analogue scale and the DASH in favor of L-PRP
after 6, 12 and 24 months. In order to make a cost utility analysis, the VAS-scores
were mapped to EQ-5D, using the method suggested in Dixon et al 2011. In this
study the derived utility values for a series of EQ-5D health states replaced the pain
value with the NPRSVAS, thereby allowing a greater range of pain intensities to be
captured and included in economic analyses. This raises an issue regarding trans-
ferability of QALY-values. Nord E. 1991 concludes that QALY-values elicited in
Norway, The Netherlands, England or Sweden can be used for medical decision
making purposes in any of the other three countries.RESULTS:The results show an
incremental cost effectiveness ratio of € 5 000 per QALY. This is well within what is
considered cost effective in Norway. The probabilistic analysis demonstrates that
the probability of L-PRP being the cost effective alternative is as high as 99% even
when the willingness to pay for additional QALY is as low as € 13 000.
CONCLUSIONS: Compared to corticosteroids, treating lateral epicondylitis with
L-PRP represents the cost effective treatment strategy in Norway.
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OBJECTIVES: The purpose of this study was to estimate the cost-effectiveness of
two therapeutic strategies starting either with Sacral Neuromodulation (SNM) or
Botulinum Neurotoxin A (BTX-A) in the treatment of overactive bladder (OAB) wet
in Italy. METHODS: A 10-year decisional model was developed to assess costs and
outcomes (Quality-Adjusted Life Years – QALYs – gained) associated with the two
pathways from the perspective of the Italian National Healthcare System (INHS).
Clinical inputs were derived from the literature review and validated by key clini-
cians in Italy. Unit costs were derived from public sources. Costs for hospital pro-
cedures and inpatient stay were derived from one of the centres involved in the
study to reflect real costs incurred for SNM implant. Univariate sensitivity analyses
(DSA) were conducted to determine whether results were insensitive to variations
in uncertain parameters. Probabilistic sensitivity analyses (PSA) were performed to
derive cost-effectiveness acceptability curves. RESULTS: Preliminary results
showed that at 10 years SNM is a cost-effective strategy. Cumulative costs were
€33,897 and €33,572 while cumulative QALYs were 7.55 and 6.80 for SNM and BTX-A
respectively. A 4% decrease of incontinence episodes was also observed for SNM
compared with BTX-A. DSA demonstrated the robustness of the results. PSA re-
sults suggested that 99.9% of the 1000 Monte Carlo iterations fell within a €30,000
cost-effectiveness threshold considered acceptable for a marginal unit of
effectiveness. CONCLUSIONS: A therapeutic strategy starting with SNM compared
to one starting with BTX for patients with idiopathic OAB-wet is cost-effective for
the Italian INHS.
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COST-EFFECTIVENESS OF CATHETER ABLATION VERSUS ANTIARRHYTHMIC
DRUG THERAPY FOR THE TREATMENT OF ATRIAL FIBRILLATION IN THE UK
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized
by uncoordinated atrial activation involving a rapid and irregular heartbeat. Its
prevalence has been increasing worldwide. Antiarrhythmic drug therapy is a com-
monly-used treatment for paroxysmal AF , and catheter ablation has become an
important treatment alternative. The purpose of this study was to assess the cost-
effectiveness of catheter ablation compared to antiarrhythmic drug (AAD) therapy
for the treatment of paroxysmal AF in the UK. METHODS: A Markov simulation
model was developed for a hypothetical cohort of 55-year-old patients with drug-
refractory paroxysmal AF and a low stroke risk. The model treatment arms were
catheter ablation and AAD mono-therapy. The model was created to assess the
costs and quality-adjusted life-years over a lifetime horizon. Clinical efficacy of
catheter ablation and AAD therapy were modeled based on the results of a recently
published randomized controlled trial (Wilber et al., 2010). Utilities and other tran-
sition probabilities were drawn from the published literature. Costs were specific to
the UK. RESULTS: The incremental cost-effectiveness ratio for catheter ablation
versus AAD therapy ranged from £12,500 to £15,300 per quality-adjusted life-year.
Over a lifetime horizon, the quality-adjusted life expectancy ranged from 11.75 to
12.20 years for catheter ablation compared to 11.00 to 11.35 years for AAD therapy.
Model results were most sensitive to ablation costs, probability of successful abla-
tion treatment, probability of revision to AF, and probability of successful AAD
therapy. CONCLUSIONS: Catheter ablation appears to be cost-effective compared
to AAD therapy among patients who had drug refractory paroxysmal AF in the UK
population when using a cost-effectiveness threshold of £20,000.
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A FIVE-YEAR MARKOV MODEL EVALUATING THE COST-UTILITY OF NASHA/DX
FOR THE TREATMENT OF FECAL INCONTINENCE: A UNITED STATES
PERSPECTIVE
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OBJECTIVES: To estimate the costs and outcomes associated with the treatment of
NASHA/Dx (Solesta®) for fecal incontinence (FI) compared with sacral nerve stim-
ulation (InterStim®) and anal sphincteroplasty. METHODS: A five-year Markov
model was developed to analyze the cost-utility associated with: 1) NASHA/Dx; 2)
sacral nerve stimulation (SNS); and 3) anal sphincteroplasty (AS) after failure of
conservative therapy. Costs and outcomes were based on the published literature
and other public sources. Costs and QALYs were discounted at a rate of 3% annu-
ally. Probability sensitivity analyses were used to estimate the robustness of the
base case and scenarios. The probability and utility variables were modeled as
beta-distributions; costs were modeled as lognormal distributions. One-way sen-
sitivity analyses were used to evaluate the impact of variations related to key cost
variables. A willingness-to-pay (WTP) analysis was conducted for a threshold of
twice the US GDP per capita; cost-effectiveness acceptability curves were con-
structed. ICERs less than the specified threshold are considered cost-effective.
RESULTS: The base case Markov model yielded an incremental cost-effectiveness
ratio (ICER) for NASHA/Dx vs. conservative therapy (CT) of $30,123 / QALY (Quality
Adjusted Life Year). The ICER for SNS vs. CT was $51,187 / QALY; the ICER for AS vs.
CT was $56,564 / QALY. A sensitivity analysis for the long-term effectiveness of
NASHA/Dx resulted in an ICER of $40,327 for NASHA/Dx vs. CT. Probabilistic sen-
sitivity analysis demonstrated that NASHA/Dx was cost-effective for 78% of the
simulations at a threshold of $70,654 / QALY gained. CONCLUSIONS: For FI pa-
tients, NASHA/Dx has demonstrated cost-effectiveness. Due to higher acquisition
costs, SNS and anal sphincteroplasty were associated with larger ICERs. Sensitivity
analyses indicated NASHA/Dx was cost-effective under all scenarios modeled.
WTP analyses demonstrated that NASHA/Dx was highly probable to be cost-effec-
tive in the US context.
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OBJECTIVES: To evaluate the metabolic effect of adding continuous glucose mon-
itoring (CGM) to insulin pump therapy and the impact of CGM on medical resource
utilization METHODS: Eighty-one adults & seventy-two children with Type 1 dia-
betes participated in a multicenter, randomized, controlled, cross-over study. Fol-
lowing a one month run-in period, subjects were randomized to CGM Sensor-ON or
Sensor-OFF arms for six months, following a four month wash-out period subjects
crossed over to the other treatment arm for six additional months. Health care
resources utilization data was collected for both arms at baseline and at each study
visit. RESULTS: Sensor use significantly improved glycemic control resulting in an
HbA1c reduction of -0.43% in the intention to treat population. There was no sta-
tistically significant difference in the average total daily amount of insulin used
between Sensor-ON and Sensor-OFF groups both in children or adults. There were
statistically significant reductions in the average weekly number of finger-prick
tests observed in Sensor-ON vs. Sensor-OFF period (-3 tests/week in adults and -5
tests/week in children,) resulting in 140€ (adults) and 234€ (children) yearly cost
reduction. There was no significant difference in the number of diabetes related
hospitalizations but the duration of the stay tended to be less with Sensor-ON vs
Sensor-OFF (Adults; 2.2 vs 2.5 days and Children; 1.5 vs 2.0 days). In the per-protocol
population children missed significantly less days of school during the Sensor–ON
vs. Sensor-OFF periods (13 vs 42 days, p0.0046). CONCLUSIONS: Adding CGM to
pump therapy significantly improved metabolic control in adults and children,
without increasing insulin dosage and concomitantly reducing the number of fin-
ger-prick tests. Using the sensor five or more days per week significantly reduced
absence from school in children with type 1 diabetes.
MEDICAL DEVICE/DIAGNOSTICS - Patient-Reported Outcomes & Patient
Preference Studies
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THE USE OF MULTI-CRITERIA DECISION ANALYSIS TO ELICIT COLORECTAL
CANCER SCREENING PREFERENCES
Hummel JM, Steuten L, Groothuis-Oudshoorn KGM, Mulder N, IJzerman MJ
University of Twente, Enschede, The Netherlands
OBJECTIVES: Despite the expected health benefits of colorectal cancer screening
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programs, participation rates remain low in countries that have implemented such
a screening program. Besides the diagnostic accuracy and the risks of the screening
technique that affect the health of the participants, additional factors, such as the
burden of the test, may impact the individuals’ decisions to participate. The aim of
this study it to explore the impact of preferences for the attributes of screening
tests on intention to attend a colorectal cancer screening program. METHODS: We
used a web-based questionnaire to elicit the preferences of Dutch men and woman
aged 55 to 75 years for alternative colon screening techniques, and to measure their
intention to attend the screening. The Analytic Hierarchy Process (AHP), a tech-
nique for multi-criteria analysis, was used to estimate the colorectal cancer screen-
ing preferences for iFOBT, Colonoscopy, Sigmoidoscopy and Virtual Colonoscopy.
RESULTS:We included 167 respondents that were consistent in their judgments on
the relevance of the criteria and the preferences for the screening techniques. The
results indicate that the most preferred screening methods with the highest inten-
tion to attend were Virtual Colonoscopy and iFOBT. Sensitivity and safety of the
screening methods were the strongest determinants of the overall preference for
the screening techniques. However, safety and inconvenience were most strongly
related to intention to attend. CONCLUSIONS: Even though for the long term the
respondents may recognize the high importance of diagnostic effectiveness, their
short term decision to attend the screening tests appears to be less driven by this
consideration. Our analysis suggests that inconvenience and safety will be the
strongest technique-related determinants of the respondents’ decision to partici-
pate in the new screening program in the Netherlands.
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OBJECTIVES: Although transcatheter aortic valve implantation (TAVI) is effective
and less invasive than surgery, its superiority in terms of costs and quality of life is
controversial and has not been well demonstrated in “real life” patients. The pri-
mary objective of the TEVAS study is to evaluate cost-utility of TAVI vs conven-
tional surgery and conservative treatment. In this preliminary analysis we present
clinical results, resource use, and changes in quality of life during the first month
after TAVI in a real life setting. METHODS: Candidate patients were recruited pro-
spectively at the time of indication in 7 Spanish hospitals. A centralized follow-up
was performed by phone one month after intervention. We measured utility with
EQ5D and specific quality of life with the Heart-QoL questionnaire. RESULTS: A
total of 109 patients were recruited in the TAVI group and follow-up at one month
was available for 66. Mean age: 80.8 (SD:6.6), mean logistic EuroSCORE: 14 (SD:12.6)
(median:10.32, Q1-Q3:6.2-18.6). Four patients (6%) had severe complications after
TAVI (AMI, stroke or need for a second valve) and 8 (12.1%) died in the first 30 days
after TAVI. Among survivors, EQ5D score improved significantly from baseline
(0.61, SD:0.33 to 0.72, SD:0.31; p-value:0.01) and so did the Heart-QoL overall score
(1.44, SD:0.77 to 2.07, SD:0.58; p-value0.001). During the first month of follow-up
there were a mean of 0.89 visits per patient to the family physician, 0.40 to a
specialist and 0.44 to the nurse. Six patients (10.3%) had at least one readmission
(7% for cardiovascular causes; mean hospital length of stay: 6.8 days per patient).
CONCLUSIONS: Although quality of life improves substantially in the first month
after TAVI, in preliminary analysis resource use still remains high.
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THE RELATIONSHIP BETWEEN TREATMENT SATISFACTION AND HEALTH
STATUS AMONG THOSE WITH TYPE 1 DIABETES
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OBJECTIVES: Patients with type 1 diabetes (T1D) can achieve glycemic control ei-
ther through multiple daily injections or by using insulin pump therapy (IPT). How-
ever, real-world data on these treatments is lacking. The objective of this study was
to compare the levels of treatment satisfaction between patients using IPT versus
those not and to examine the relationship between treatment satisfaction and
health status. METHODS: Unique respondents from the 2009, 2010, and 2011 U.S.
National Health and Wellness Surveys were pooled together for analysis. All re-
spondents who reported a diagnosis of T1D were included. Those using IPT were
compared with those not using IPT. The relationship between satisfaction and
health status was also examined using multiple linear regression models (control-
ling for sociodemographics and health history variables) among all T1D patients
using insulin. Health status was assessed using the SF-12v2 instrument. RESULTS:
Of the 1441 patients who reported being diagnosed with T1D and were currently
using insulin, 379 reported using IPT (26.3%). Patients using IPT reported signifi-
cantly higher levels of satisfaction with their treatment (6.0 vs. 5.8, p.05). Among
all patients with T1D and using insulin, satisfaction was significantly associated
with greater health status across all summary and domain scores of the SF-12
including: mental component summary (b1.64), physical component summary
(b0.84), bodily pain (b1.34), vitality (b3.74), physical functioning (b3.11), phys-
ical role limitations (b3.45), emotional role limitations (b2.87), general health
(b3.16), mental health (b3.34), social functioning (b3.79), and health state util-
ities (b0.02) (all p.05). Satisfaction was also significantly associated with less
impairment in daily activities (b-2.44). CONCLUSIONS: Patients using IPT re-
ported significantly greater satisfaction and satisfaction was associated with
greater health status and reduced activity impairment. Further research is neces-
sary to uncover the mechanisms of these relationships but these findings suggest
that the patient’s perspective of their treatment is strongly associated with health
outcomes.
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DOES PRESENTING FOLLOW-UP TEST INFORMATION AFFECT PEOPLE’S
PREFERENCES FOR COLORECTAL CANCER SCREENING TESTS? A DISCRETE
CHOICE EXPERIMENT
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OBJECTIVES: Fifty-one percent of people do not participate in non-invasive colo-
rectal cancer screening. One of the reasons may be the prospect of a future invasive
follow-up test (colonoscopy). We investigate how follow-up test information af-
fects peoples’ participation decision and screening test preferences and expect a
negative effect on participation when colonoscopy is specified as follow-up test.
METHODS: Attributes and levels in the DCE are based on a literature review and
analysis of CRC related mortality-risk (data Erasmus MC). We created a labeled and
blocked efficient design with zero priors and restrictions in Ngene. The labels rep-
resent three different screening tests (a stool-test, blood-test, combi-test) and a
non-participation option. Two follow-up test specification versions and 3 blocks
resulted in six different web-based survey versions of 12 choice sets each. The
colonoscopy specification version presents respondents an additional follow-up
test attribute with colonoscopy as a fixed attribute level and detailed colonoscopy
information. The non-colonoscopy specification version doesn’t present respon-
dents a follow-up test and follow-up test information. Respondents were randomly
assigned to one of the survey versions. Data of 631 Dutch respondents, aged 55-75
years, is used in the analysis. RESULTS: MNL model results show a positive signif-
icant effect on screening test choice for the attributes sensitivity, risk reduction,
and level of evidence, and a negative effect of 1-specificity. The significant negative
interaction effects of the alternative specific constants with follow-up test specifi-
cation indicate that uptake would be lower in case a colonoscopy is specified (83.8%
versus 88.6%). Furthermore, the difference between the (more preferred) combi-
test relative to the other tests diminishes for the colonoscopy specification. A
nested logit model doesn’t indicate scale differences. CONCLUSIONS: People’s
screening test preferences are affected by invasive follow-up test (colonoscopy)
information presented in the survey. This result is interesting for policy makers
that aim to optimize uptake.
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OBJECTIVES: Glycemic control for patients with type 1 diabetes (T1D) can be
achieved either through multiple daily injections or through insulin pump therapy
(IPT). Currently, there is a lack of real-world data on the differences in these treat-
ment options, particularly as they relate to patient-reported outcomes. The objec-
tive of this study was to investigate the effect of IPT on health status among pa-
tients with T1D. METHODS: Data from unique respondents from the 2009, 2010,
and 2011 U.S. National Health and Wellness Surveys were used. Among respon-
dents who reported a diagnosis of T1D and reported using insulin, those who
reported using IPT were compared with those who were not using IPT on summary
and domain scores of the SF-12v2 using general linear models controlling for so-
ciodemographic and health history differences. RESULTS: A total of 1,441 patients
reported being diagnosed with T1D and were currently using insulin. Of these
patients, 379 reported using an insulin pump (26.3%). Patients using an insulin
pump had been diagnosed for longer (26.8 vs. 21.2 years) and were significantly
more likely to be female (53.8% vs. 43.3%), be non-Hispanic white (87.6% vs. 68.6%),
have an annual household income of $75K or more (27.7% vs. 18.9%), and possess
health insurance (95.05 vs. 84.8%) (all p.05). Adjusting for these differences, pa-
tients using an insulin pump reported significantly better physical health status
(44.76 vs. 42.51) and health utilities (0.71 vs. 0.68). Similar significant differences
were observed on domain scores of the SF-12. CONCLUSIONS: Although T1D pa-
tients with greater health care access were more likely to use IPT, even after ad-
justing for these differences, a significant effect of IPT was observed on health
status. These results suggest that IPT may be associated with greater real-world
effectiveness, though additional research is necessary.
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CONTRIBUTION OF INDIVIDUAL EQ-5D DIMENSIONS TO IMPROVED QUALITY
OF LIFE AFTER BALLOON KYPHOPLASTY FOR VERTEBRAL COMPRESSION
FRACTURES
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OBJECTIVES: The acute back pain arising in relation to vertebral compression frac-
tures (VCFs) has traditionally been viewed as the most important driver for the
health-related quality of life (QoL) decrement associated with the fracture. The
objective was to quantify the impact of different health dimensions on overall
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